Search Results

Global Business

30+ Countries

Diversified Markets

Many 1^st to Market Products

500+ Products

Specialty Segments

Superior Formulation Development Capabilities

800+ Scientists

5% of Revenue

Clear Strategy, Consistent Performance

Ajanta Pharma is a specialty pharmaceutical company providing quality medicines across 30+ countries in the world. We enjoy leadership in multiple molecules and therapeutic segments through 1^st to Market products.

Differentiated & Smart Product Portfolio

At Ajanta, we produce a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients. We clearly understand our customers’ needs and use cutting-edge technology to present innovative solutions.

The Innovation Edge

Ajanta’s R&D has been consistently developing difficult and complex products to harness patient needs. Our 800+ scientists embrace technology to find appropriate solutions to address the challenges faced by patients across the globe.

Providing Quality Products

Outstanding quality systems, skilled and knowledgeable team and the best in class equipment at our 7 manufacturing facilities ensure that our patients get nothing but the best in quality.

Ms. Simi Thapar (Non-Executive, Independent Director)

Ms. Thapar is an expert in asset financing and leasing solutions that help corporates forward their ESG goals.  She is currently working as Chief Country Officer & Director with CSI Renting India Pvt. Ltd., a multinational organization with presence in 50 countries, offering equipment leasing and lifecycle solutions to the enterprise segment. It is subsidiary of Tokyo Century Corporation, Japan. Prior to this, she was with Tata Capital for 8 years as a business head. She has been a speaker and panellist at various industry forums in India, USA, Hongkong, Singapore, Dubai and London for talks on asset financing, leasing solutions, women leadership and women in BFSI. She is a member of Diversity & Inclusion, and CSR committees of the American Chamber of Commerce in India. She has been instrumental in setting up NGO for economic empowerment of disadvantaged women. She is also member of NGOs for initiatives in the field of spiritual wellbeing, education, and healthcare for the disadvantaged community. She has a post graduate degree in commerce from Mumbai University along with Diploma in Business Finance & Business Management. She has also secured ‘Masters in Change’ degree from INSEAD, Singapore.

Mr. Rajesh Dalal (Non-Executive, Independent Director)

Mr. Dalal is a healthcare industry veteran with over four-decades experience in the field of business management and strategic advisory. In 1980, he joined Johnson & Johnson India as a product manager and rose through the ranks to become the managing director at J&J Medical India, the medical device business. He was also Vice President (Asia) M&A at J&J Medical Asia and was simultaneously an Executive Director at J&J Medical China till 2010. Post retirement from J&J, he became a venture partner with OrbiMed Asia Fund where he was associated for the next 4 years. He has been advisor to several private equity firms like Tata Healthcare Fund, Advent, Baring Asia/ PWC, Gaja Capital, Khazana and multinational corporations like Philips Netherlands, Intuitive Surgical USA, Alltech USA/ China, etc. He is also independent director on the Boards of Entero Healthcare Solutions Ltd. and Ascent Meditech Ltd. He holds an MBA from Jamnalal Bajaj Institute of Management Studies and B. Tech from Indian Institute of Technology, Madras.

Mrs. Medha Joshi (Non-Executive, Independent Director)

Mrs. Medha Joshi is a banking industry stalwart with expertise in an array of subjects including risk management and forensic audit. She retired from IDBI Bank as Chief General Manager after 35-years of service. During her association with IDBI Bank she managed Corporate Banking, Investments, Human Resources, Risk Management, Retail banking, Rehabilitation Finance, Corporate Finance and Merchant Banking. Post retirement, she has been associated with HDFC Ergo as advisor and with National Stock exchange (NSE) / Bombay Stock Exchange (BSE) as Arbitrator. She is a Certified Associate of Indian Institute of Bankers (CAIIB) and a degree holder in MBA.

Mr. David Rasquinha (Non-Executive, Independent Director)

Mr. David is an international finance veteran with over 40 years’ experience in export credits and cross-border financial transactions. He superannuated from India Exim Bank as the Managing Director and Chief Executive Officer after serving it for nearly four decades. During his tenure with India EXIM bank, he served as a member on several Working Groups set up by the Reserve Bank of India as well as the Government of India for facilitation measures for exporters, working capital finance etc. He is an expert analyst and speaker on the Indian economy and other key issues. His insights on export credit and the Indian economy are often sought in panel discussions and seminars, by overseas equity and fixed-income investors in Japan, Singapore, Hong Kong, London, USA. Mr. David holds a first-class graduate degree in Economics from Bombay University and a post graduate degree in Business Management from the XLRI, Jamshedpur where he was awarded the Gold Medal in Economics. He is also an Independent Director on the Boards of Ion Exchange Ltd. and Unity Small Finance Bank.

Mr. Rajesh Agrawal (Joint Managing Director)

Mr. Rajesh Agrawal is Jt. Managing Director of Ajanta Pharma. He is a graduate in Business Studies from University of Buckingham, UK and MBA from Bentley College, USA. He joined the company in 1999. It is under his leadership that the company made a corporate turnaround and emerged as a leading specialty focused company. He has transformed Ajanta's India business to one of the best performing markets for the company. His keen focus on new products and go-to-market strategy has made Ajanta a leading player in the segments of Cardiology, Dermatology, Ophthalmology, and Pain management in a very short period. Most of the new product launches, being first of its kind in the Indian market, are credited to his business acumen. He has also replicated this success in Philippines, where Ajanta Pharma Philippines features among the fastest growing companies. His core competencies include business acumen, vision, strategic thinking and human resource management.

Mr. Yogesh Agrawal (Managing Director)

Mr. Yogesh Agrawal is Managing Director of Ajanta Pharma. A management graduate from Johnson & Wales University, USA; he joined the company in 1996 and grew-up the ranks to become Managing Director. It is under his leadership that Ajanta Pharma made a corporate turnaround and emerged as a leading branded generic player from India having strong footprint in its chosen markets. He spearheads Ajanta's foray in the regulated and emerging international markets. He has transformed the company’s research program and manufacturing capabilities by setting-up state-of-art facilities that meet stringent regulatory requirements. His passion towards research and development has fuelled the company’s growth. His core competencies include strong business acumen, strategic intelligence, execution abilities and governance.

Mr. Madhusudan Agrawal (Vice Chairman)

Mr. Madhusudan Agrawal is Vice Chairman of Ajanta Pharma. He has rich experience of over 47 years in the industry. His core competencies include corporate affairs, business development, business acumen, vision, industry knowledge, international business, general management, leadership, people management, networking, public relation, etc. He contributes effectively towards social causes and philanthropic activities of the company.

Mr. Mannalal Agrawal (Chairman)

Mr. Mannalal Agrawal is Chairman of Ajanta Pharma. He has more than five decades of experience in business. With his strategic thinking, vision and leadership style he guides the board and executive management of the company on many of their strategic decisions. His core competencies include business management, industry knowledge, administration, taxation, finance and accounting. He takes keen interest in the social activities of the company.

Mission

Our mission is to Serve Global Healthcare needs through Empathy, Innovation and Technology. We believe that to ensure sustained growth, we need to clearly understand our customers needs and use cutting-edge technology to present innovative solutions with a cost-effective approach.

Vision

Be a niche player in global pharma space and to enhance value for all stakeholders. We are a value driven company. We see Ajanta making a global impact in a way that creates value for all stakeholders, through focus on niche products to fulfil emerging patient needs.

Mission

Our mission is to Serve Global Healthcare needs through Empathy, Innovation and Technology. We believe that to ensure sustained growth, we need to clearly understand our customers needs and use cutting-edge technology to present innovative solutions with a cost-effective approach.

Vision

Be a niche player in global pharma space and to enhance value for all stakeholders. We are a value driven company. We see Ajanta making a global impact in a way that creates value for all stakeholders, through focus on niche products to fulfil emerging patient needs.

Listed in Fortune 500 list of Indian companies Ranked 379^th in Revenue Generation

Listed in BT 500 ranked 211^th in Market Capitalization, 250^th in sales & 114^th in Profit

MD & Joint MD conferred as "Best CEO of The Year - Next Gen" by the hands of Dr. Raman Singh

Mr. Yogesh Agrawal Ranked 17^th in BT Top 100 CEO’s of India. Ranked 2^nd in Pharma Sector

Top Export Performer Award by the Federation of Indian Export Organisations.

Listed in Fortune 500 list of Indian companies Ranked 3^rd in wealth creation

Listed in BW Real 500

MD and Joint MD Nominated for “Forbes Leadership Award 2017”

Ajanta pharma Ranked 186^th in Next Super 100 companies by Business India

Listed in India’s most Valuable Companies by Business Today, ranked 127th in Avg. Mkt. Capitalisation & 116th in Net Profit

Ajanta Pharma Listed as Fastest Wealth Creator for the 3^rd year in a row by Motilal Oswal

MD & Joint MD conferred with TIME Young Maker of the Year award by the hands of Hon. Prime Minister Mr. Narendra Modi

Listed in "Fastest Growing Company in India" and Ranked 21^st by Outlook Business Magazine

Listed in BT 500 ranked 148^th in Market Capitalisation, 327^th in sales & 102^nd in Profit

Listed among ‘Forbes India Super 50 Companies’ for the 3^rd year in a row

Listed among Out Performers List of Outlook Business, ranked 1^st Among Stock Return

Ajanta listed among fastest growing pharma company, ranked 11^th in revenue by Businessworld

Mr. Yogesh Agrawal Ranked 6^th among India Most Valuable CEOs by Businessworld in Midcap category

Received the third largest wealth creator award from Fortune India

Best Transformational Leader Award conferred to Managing Director by ACCGs

Fortune India Presented Award as “One of the Giants of Tomorrow” by the hands of Mr. Mr. Nitin Gadkari

Fastest wealth creator in last 5 years as per a study by Motilal Oswal

Listed in Forbes India Super 50 Companies

Featured in Forbes Asia Best 200 for 3 consecutive years

Managing Director honoured with Young Entrepreneur Award by CCC in presence of Vice President of India

Managing Director nominated for Business Today CEO of the year award for two years

Listed in Top 100 Companies of Asia by Bio Spectrum Asia, Ranked 76^th

Gold Trophy for Quality Excellence from Indian Drug Manufacturer Association

Ajanta Pharma awarded 'India's Best Managed Companies' for 2022 by Deloitte

Ajanta is Great Place To Work®-Certified™ in India for the 2^nd year in a row

Ajanta Pharma USA Inc. (APUI) received DIANA award for ‘Best Overall Generic Manufacturer’ in less than $100 mn. sales category

Ajanta wins 'Outstanding Export Performance Award' from Pharmexcil in 'Formulation' category

Ajanta wins 'Excellence in Pharma Supply Chain Management'

Ajanta wins Excellence in Packaging Developed in India & Packaging Team of the Year at India Packaging Awards 2022

Ajanta wins Times Ascent Global Best Employer Brands 2023

Ajanta wins 'Maharashtra State Best Employer Brand Awards 2022' in Pharma sector

Yogesh & Rajesh Agrawal (MD & Jt. MD) recognised as 'Next Gen Leaders of the Year 2023' by Hurun India

Ajanta wins 'Golden Peacock Business Excellence Award 2024' in the Pharma sector

Ajanta entered Asia Book of Records for Largest Life Saving CPR Awareness & Training Campaign

Ajanta entered Asia Book of Records for Largest Photo Collage of CPR Workshops conducted in India

Ajanta wins 'SKOCH ESG Award 2024' for Clean & Green Energy Utilisation

Ajanta wins 'Pharma Supply Chain Champion' Award in Mid Sized firms category

Ajanta's Paithan facility recognized with 'Apex India Safe Workplace Gold Award 2023' in Pharma sector

Ajanta wins 'Apex India Green Leaf Platinum Award 2023 for Sustainability' in Pharma sector

Our Flagship product - Trimol wins Most Popular Brand for Headache Relief in Uzbekistan

Ajanta's Dahej Facility wins Silver Medal from National Awards for Manufacturing Competitiveness (NAMC)

Ajanta wins Packaging Team of the Year at India Packaging Awards 2024

Ajanta was presented 'One Decade Excellence in CSR' Award by Shri Ramesh Bais and Mr. Kailash Satyarthi

Mr. Rajesh Agrawal (Jt. MD) presented with 'Exceptional Contribution in Pharma & Healthcare' Award by Rotary International

Ajanta wins 'Outstanding Export Performance Award' from Pharmexcil in 'Formulation' category

Ajanta's Dahej facility recognized with 'Best Manufacturing Facility Award' at the Pharma Manufacturing & Automation Excellence (PM & AE) Awards

Ajanta's Paithan facility honoured with one Platinum and two Silver Kaizen awards at the 50th CII National Kaizen Competition

Ajanta's Guwahati Facility honoured with 'Best Labour Law Compliant Establishment' by Government of Assam

Ajanta Pharma is a specialty pharmaceutical company providing quality medicines across 30+ countries in the world.

We enjoy leadership in multiple molecules and therapeutic segments through 1st to market products.

Ajanta is the pioneer in generic anti-malaria product of Artemether-Lumefantrine (immediate release and dispersible tablets) combination in Africa.

We were the 1st generic player pre-qualified by WHO Geneva for this product and hold leadership position in the segment. With focus on Africa’s hardest malaria hit countries we have been able to treat over 1 billion patients in about a decade. We are committed to bringing more of our medicines to more people, no matter where they are.

We provide comprehensive range of specialty branded generic products targeting broad spectrum of chronic and acute therapies. We clearly understand our customers’ needs and use cutting-edge technology to present innovative solutions.

We carefully identify gaps in our markets and commit ourselves to get the products to market places ahead of the competition giving huge competitive advantage of 1^st to market. Our products have the hallmark of technology-based differentiation and cover the full range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams and liquids.

Ajanta Pharma is an established player in emerging markets with presence in more than 30 countries spread across Africa, South East Asia, West Asia and CIS.

We have built an outstanding brand equity in these markets with sales being driven by its Branded Generic products.

At Ajanta Pharma we are proud to be among the top 30 companies in India with 26th rank in Sept 2024 as per IQVIA.

In last 10 years, Ajanta has galloped ranking in India market with clear focus on 4 fast growing specialty therapeutic segments, supported by launching first of its kind innovative products in the market. Today Ajanta is in an enviable position in all the 4 major therapeutic segments of Cardiology, Dermatology, Ophthalmology and Pain Management with many of our brands enjoying leadership positions in respective sub-therapeutic segments. We have been growing faster than the industry in all these segments.

Ajanta Pharma has established itself as a meaningful niche player in the US generics market.

Our strategy is to have a selective play in this market with launching limited competition products. Currently we have 55 ANDA approvals (includes 2 tentative), out of which 46 are commercialized. Ajanta is awaiting US FDA approval for 22 ANDAs. We plan to file 8-12 ANDAs every year. All the products are marketed through our subsidiary Ajanta Pharma USA Inc. For more details on this subsidiary, please click here.

Manager - Finance (1)

Accounts, Finance, Legal, CA / MBA - Finance, 4 - 5 years, Head Office - Kandivali

ASST.OFFICER-QC (03)

QUALITY CONTROL, B.PHARM /M.SC, 01 - 02 YEARS, CHITEGAON

Officer - Qualification - Maintenance (1)

Manufacturing , B.E (Mechanical/Electrical), 5 - 8 Years, Dahej, Gujarat

Officer - Maintenance Store (1)

Manufacturing , Any Graduate, 4 to 8 Years, Dahej, Gujarat

Assistant - HVAC - Maintenance (1)

Manufacturing , I.T.I - Electrician, 4 to 8 Years, Dahej, Gujarat

Manager - E BMR - Production (1)

Manufacturing , B. Pharm/M. Pharm, 13 to 16 Years, Dahej, Gujarat

Executive - QMS - Production (1)

Manufacturing , B. Pharm/M. Pharm, 10 -12 Years, Dahej, Gujarat

Asst. Executive - Production (1)

Production, B. Pharm/M. Pharm, 10 -12 Years, Dahej, Gujarat

Officer/Sr. Officer - Production & Packing (9)

Manufacturing , B. Pharm/M. Pharm, 2 to 8 years, Dahej, Gujarat

Production Associate (8)

Manufacturing , Any I.T.I, Any Diploma, 3 to 10 Years, Dahej, Gujarat

Executive (1)

HR, Any Graduate, 6 to 8 Years, Dahej, Gujarat

Associate - Warehouse (2)

Manufacturing , Any I.T.I, 3 to 7 Years, Dahej, Gujarat

Assistant (7)

QC, Any I.T.I, 2 to 8 years, Dahej, Gujarat

Officer/Sr. Officer (10)

QC, B.Sc./M.Sc./B.Pharm/M.Pharm , 4 to 8 Years, Dahej, Gujarat

Officer/Sr. Officer (6)

QA, B. Pharm/M. Pharm, 4 to 8 Years, Dahej, Gujarat

Regional Logistic Manager (01)

Distribution, Any Graduate, 5 to 10 years, Mumbai

Executive / Sr. Executive (Inventory) (01)

Distribution, Any Graduate, 5 to 10 years, Mumbai

Manager - Legal (1)

Accounts, Finance, Legal, LLB / LLM, Diploma in IPR, 4 - 5 years, Head Office - Kandivali

Executive - Legal (1)

Accounts, Finance, Legal, LLB, 1 - 2 years, Head Office - Kandivali

OFFICER MAINTENANCE-ELECTRICAL (1)

MAINTENANCE, B.E/DIPLOMA-ELECTRICAL, 6, PITHAMPUR, INDORE, MP

OFFICER-UTILITY (4)

MAINTENANCE, B.E/DIPLOMA-MECHANICAL, 6, PITHAMPUR, INDORE, MP

OFFICER-UTILITY (1)

MAINTENANCE, B.E/DIPLOMA-ELECTRICAL, 8, PITHAMPUR, INDORE, MP

BOILER OPERATOR (2)

MAINTENANCE, DIPLOMA-MECHANICAL, 6, PITHAMPUR, INDORE, MP

OPERATOR UTILITY-ELECTRICAL (2)

MAINTENANCE, ITI, 6, PITHAMPUR, INDORE, MP

OPERATOR UTILITY-MECHANICAL (2)

MAINTENANCE, ITI-MECHANICAL/FITTER, 6, PITHAMPUR, INDORE, MP

HVAC OPERATOR (2)

MAINTENANCE, ITI, 6, PITHAMPUR, INDORE, MP

Research Associate- Method Development (2)

ADL-ANDA, M. Sc (Chemistry), 2- 4 Years, R&D, Mumbai

Research Associate- Method Development (2)

ADL-ANDA, M. Sc (Chemistry), 2- 4 Years, R&D, Mumbai

Sr. Research Associate- Method Development (2)

ADL-ANDA, M. Sc (Chemistry), 5- 7 Years, R&D, Mumbai

Research Associate- Method Development (2)

ADL-ROW, M. Sc (Chemistry), 2- 4 Years, R&D, Mumbai

Sr. Research Associate- Method Development (2)

ADL-ROW, M. Sc (Chemistry), 5- 7 Years, R&D, Mumbai

Research Associate- Method Validation (2)

ADL-ROW, M. Sc (Chemistry), 2- 4 Years, R&D, Mumbai

Sr. Research Associate- Method Validation (2)

ADL-ANDA, M. Sc (Chemistry), 5- 7 Years, R&D, Mumbai

Executive/ Sr. Executive - Mobile App (1)

IT, BE/MCA/MSc comp. Science, 5-7 years, HO, Mumbai

Executive/ Sr. Executive – PHP Developer (1)

IT, BE/MCA/MSc comp. Science, 5- 7 Years, HO, Mumbai

Executive/ Sr. Executive (1)

IT, BE/MCA/MSc comp. Science, 5- 7 Years, HO, Mumbai

Over 7,900+ driven, motivated and talented employees spread across different geographies are our greatest asset. Our success is attributed to committed Ajantaites working towards a common goal. We believe in nurturing the talent and providing them required resources, so that they can reach their maximum potential.

 

We operate with strong values of excellence, integrity and transparency which inspire leadership and knowledge sharing.  We provide opportunities and resources to our employees to learn, innovate, experiment and implement.

We offer challenging and exciting career opportunities for talented and passionate professionals.

Our employees are highly motivated, driven and talented group of people who come from diverse backgrounds. 

At Ajanta, we have always strived to make the world around us a better place. Corporate Social Responsibility (CSR) is an integral part of our business and commitment for sustainable development of underprivileged communities. It promises brighter future for every life we touch.

As per the company’s CSR policy, 3 major focus areas have been identified for our activities which includes healthcare, education and community development apart from other areas prescribed under the regulation.

Ajanta Pharma Ltd disclaims all warranties, express or implied, including without limitation, the implied warranties of title, non-infringement, merchantability and fitness for a particular purpose, with respect to this web site and the material on this web site.

Ajanta Pharma Ltd also makes no warranties as to whether the information accessible on this web site is accurate, complete or current.

Clear Strategy, Consistent Performance

Ajanta Pharma is a specialty pharmaceutical company providing quality medicines across 30+ countries in the world. We enjoy leadership in multiple molecules and therapeutic segments through 1^st to Market products.

Differentiated & Smart Product Portfolio

At Ajanta, we produce a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients. We clearly understand our customers’ needs and use cutting-edge technology to present innovative solutions.

The Innovation Edge

Ajanta’s R&D has been consistently developing difficult and complex products to harness patient needs. Our 800+ scientists embrace technology to find appropriate solutions to address the challenges faced by patients across the globe.

Providing Quality Products

Outstanding quality systems, skilled and knowledgeable team and the best in class equipment at our 7 manufacturing facilities ensure that our patients get nothing but the best in quality.

Annual Report FY 2021-22

2021-22

Business Responsibility and Sustainability Report FY 2021-22

2021-22

Impact Assessment Report

2021-22

Draft Annual Return FY 2021-22

2021-22

Annual Report FY 2020-21

2020-21

Disclosures w.r.t. Stock Options

2021-22

Business Responsibility Report FY 2020-21

2020-21

Draft Annual Return FY 2020-21

2020-21

Annual Report FY 2019-20

2019-20

Business Responsibility Report FY 2019-20

2019-20

Disclosures w.r.t. ESOS 2011 and SBIP 2019 forming part of DR for FY 2019-20

2019-20

Annual Report FY 2018-19

2018-19

Business Responsibility Report FY 2018-19

2018-19

Disclosures w.r.t. Employees’ Stock Option Scheme 2011 forming part of DR for FY 2018-19

2018-19

Annual Report FY 2017-18

2017-18

Business Responsibility Report FY 2017-18

2017-18

Subsidiary Accounts FY 2018

2017-18

Subsidiary Accounts FY 2019

2018-19

Subsidiary Accounts FY 2020

2019-20

Subsidiary Accounts FY 2021

2020-21

Subsidiary Accounts FY 2022

2021-22

Annual Report FY 2016-17

2016-17

Annual Report FY 2015-16

2015-16

Annual Report FY 2014-15

2014-15

Subsidiary Accounts FY 2023

2022-23

Disclosures w.r.t. Stock Options

2022-23

Annual Return FY 2022-23

2022-23

Annual Report FY 2022-23

2022-23

Disclosures w.r.t. Stock Options

2021-22

Draft Annual Return FY 2023-24

2023-24

Annual Report FY 2023-24

2023-24

Disclosure w.r.t. Stock Options

2023-24

Subsidiary Accounts FY 2024

2023-24

Mr. David Rasquinha

Chairman, Audit Committee

Mr. Mannalal Agrawal

Member, Audit Committee

Mr. Rajesh Dalal

Member, Audit Committee

Ms. Simi Thapar

Member, Audit Committee

Mr. Mannalal Agrawal

Chairman, Stakeholders’ Relationship Committee

Mr. Rajesh Agrawal

Member, Stakeholders’ Relationship Committee

Ms. Simi Thapar

Member, Stakeholders’ Relationship Committee

Mr. Mannalal Agrawal

Chairman, Corporate Social Responsibility Committee

Mr. Madhusudan Agrawal

Member, Corporate Social Responsibility Committee

Mr. Yogesh Agrawal

Member, Corporate Social Responsibility Committee

Ms. Medha Joshi

Member, Corporate Social Responsibility Committee

Mr. Rajesh Dalal

Chairman, Nomination & Remuneration Committee

Mr. David Rasquinha

Member, Nomination & Remuneration Committee

Ms. Medha Joshi

Member, Nomination & Remuneration Committee

Mr. Yogesh Agrawal

Chairman, Executive Committee

Mr. Madhusudan Agrawal

Member, Executive Committee

Mr. Rajesh Agrawal

Member, Executive Committee

Mr. Yogesh Agrawal

Chairman, Risk Management Committee

Mr. Rajesh Agrawal

Member, Risk Management Committee

Mr. Rajesh Dalal

Member, Risk Management Committee

Mr. Arvind Agrawal

Member, Risk Management Committee

Outcome of Board meeting regarding buyback

2018-19

Record Date Intimation

2018-19

Public Announcement

2018-19

Draft Letter of Offer

2018-19

Form SH-4

2018-19

Letter of Offer

2018-19

Tender Form - Demat

2018-19

Tender Form - Physical

2018-19

Intimation of Buy Back of Shares

2021-22

Outcome of Board meeting regarding buyback

2020-21

Board Resolution for Buyback

2020-21

Public Announcement

2020-21

Draft Letter of Offer

2020-21

Form SH-4

2020-21

Tender Form - Demat

2020-21

Letter of Offer

2020-21

Ajanta Pharma Limited - Advertisement

2020-21

Affidavit Declaration of Solvency

2020-21

Annual Report 2017-2018

2020-21

Annual Report 2018-2019

2020-21

Annual Report 2019-2020

2020-21

Escrow Agreement

2020-21

Firm Arrangement Certificate

2020-21

Maximum Permissible Limit Certificate

2020-21

Opinion on Taxation

2020-21

Memorandum and Articles of Association

2020-21

SEBI Observation letter

2020-21

Intimation of Record Date

2021-22

Outcome of Board Meeting

2021-22

Public Announcement

2021-22

Board Resolution for Buy-back

2021-22

Filing of Draft Letter of Offer

2021-22

Demat Tender Form

2021-22

Form SH-4

2021-22

Letter of Offer

2021-22

Physical Tender Form

2021-22

Post Buyback Public Announcement

2021-22

Intimation of Board Meeting

2022-23

Outcome of Board Meeting

2022-23

Intimation of record date

2022-23

Filing of PA and Board resolution with SEs (2023)

2022-23

Filing of Letter of Offer

2022-23

Intimation for Post Buyback Public Announcement

2022-23

Completion of extinguishment

2022-23

Board Meeting Intimation of Buy Back

2024-25

Outcome of Board Meeting

2024-25

Intimation of Record Date for Buy Back

2024-25

Public Announcement - Buy Back

2024-25

Board Resolution - Buy Back

2024-25

Buy Back Letter of Offer

2024-25

Post Public Announcement – Buy Back

2024-25

Completion of Extinguishment

2024-25

Details of Compliance Officer & Nodal Officer

Mr. Gaurang Shah (Sr. VP - Legal & Company Secretary), Ajanta Pharma Limited Ajanta House, Charkop, Kandivli West, Mumbai 400 067. India, +91 22 66061000, +91 22 66061200, investorgrievance@ajantapharma.com

Registrar and Transfer agents

Link Intime India Private Ltd, Unit: Ajanta Pharma Limited C 101, 247 Park,L B S Marg, Vikhroli West, Mumbai 400 083, India., +91 22 49186000, +91 22 49186060, rnt.helpdesk@linkintime.co.in

For Analysts & Institutional Investors

Rajeev Agarwal, , +91 22 66061377, , rajeev.agarwal@ajantapharma.com

For Analysts & Institutional Investors

Abhineet Kumar, , +91 22 6606 1814, , abhineet.kumar@ajantapharma.com

Deputy Nodal Officer for IEPF Authority

‎ , Ajanta Pharma Limited Ajanta House, Charkop, Kandivli West, Mumbai 400 067. India, +91 22 66061000, , investorgrievance@ajantapharma.com

For share related queries:

For downloading formats:

Revenue from Operations (₹ cr.)

EBITDA and Margin (₹ cr./ %)

Net Profit and Margin (₹ cr./ %)

RoNW (%) ¹

RoCE (%) ²

EPS (₹) ³

Corporate Governance Report – Q4 FY 2018-19

2018-19

Corporate Governance Report – Q3 FY 2018-19

2018-19

Corporate Governance Report – Q2 FY 2018-19

2018-19

Corporate Governance Report – Q1 FY 2018-19

2018-19

Corporate Governance Report – Q4 FY 2019-20

2019-20

Corporate Governance Report – Q3 FY 2019-20

2019-20

Corporate Governance Report – Q2 FY 2019-20

2019-20

Corporate Governance Report – Q1 FY 2019-20

2019-20

Corporate Governance Report – Q4 FY 2020-21

2020-21

Corporate Governance Report – Q3 FY 2020-21

2020-21

Corporate Governance Report – Q2 FY 2020-21

2020-21

Corporate Governance Report – Q1 FY 2020-21

2020-21

Corporate Governance Report – Q4 FY 2021-22

2021-22

Corporate Governance Report – Q3 FY 2021-22

2021-22

Corporate Governance Report – Q2 FY 2021-22

2021-22

Corporate Governance Report – Q1 FY 2021-22

2021-22

Corporate Governance Report - Q1 FY 2022-23

2022-23

Corporate Governance Report – Q4 FY 2015-16

2015-16

Corporate Governance Report – Q3 FY 2015-16

2015-16

Corporate Governance Report – Q2 FY 2015-16

2015-16

Corporate Governance Report – Q1 FY 2015-16

2015-16

Corporate Governance Report – Q4 FY 2016-17

2016-17

Corporate Governance Report – Q3 FY 2016-17

2016-17

Corporate Governance Report – Q2 FY 2016-17

2016-17

Corporate Governance Report – Q1 FY 2016-17

2016-17

Corporate Governance Report – Q4 FY 2017-18

2017-18

Corporate Governance Report – Q3 FY 2017-18

2017-18

Corporate Governance Report – Q2 FY 2017-18

2017-18

Corporate Governance Report – Q1 FY 2017-18

2017-18

Corporate Governance Report - Q2 FY 2022-23

2022-23

Corporate Governance Report - Q3 FY 2022-23

2022-23

Corporate Governance Report - Q4 FY 2022-23

2022-23

Corporate Governance Report – Q1 FY 2023-24

2023-24

Corporate Governance Report – Q2 FY 2023-24

2023-24

Corporate Governance Report – Q3 FY 2023-24

2023-24

Corporate Governance Report – Q4 FY 2023-24

2023-24

Corporate Governance Report – Q1 FY 2024-25

2024-25

Corporate Governance Report – Q2 FY 2024-25

2024-25

Corporate Governance Report – Q3 FY 2024-25

2024-25

Draft letter of re-appointment

Directors Familiarisation Programme

Change/ variation of Nomination

SH-14

Declaration of Nomination form

SH-13

Request for issue of Duplicate Certificate and other Service Requests

ISR-4

Declaration for opting-out of Nomination by holders of physical securities in Listed Companies

ISR-3

Confirmation of Signature of securities holder by Banker

ISR-2

Registration of PAN, KYC details or Changes/ updation

ISR-1

CSR annual action plan for 2021-2022

2021-22

CSR annual action plan for 2022-2023

2022-23

CSR annual action plan for 2023-2024

2023-24

CSR annual action plan 2024-2025

2024-25

Policy on Related Party Transactions

Whistle Blower Policy

Policy on Material Subsidiaries

Policy for determination of materiality

CSR Policy

Code of Practices & Procedures for Fair Disclosure

Code of Conduct for Independent Directors

Code of Conduct for Directors and Senior Management

Archival Policy

Dividend Policy

Policy for Remuneration of Directors and Employees

Policy for Determining Qualifications of Directors

Business Responsibility Policies

Risk Management Policy & Plan

Third Party Code of Conduct

Policy on Board Diversity

Earnings Call Transcript Q1 (Apr-Jun) 2021-22

2021-22

Press Release Q1 (Apr-Jun) 2021-22

2021-22

Earnings Call Transcript Q2 (Jul-Sep) 2021-22

2021-22

Press Release Q2 (Jul-Sep) 2021-22

2021-22

Earnings Call Transcript Q3 (Oct-Dec) 2021-22

2021-22

Press Release Q3 (Oct-Dec) 2021-22

2021-22

Earnings Call Transcript Q4 (Jan-Mar) 2021-22

2021-22

Press Release Q4 (Jan-Mar) 2021-22

2021-22

Press Release Q1 (Apr-Jun) 2020-21

2020-21

Press Release Q2 (Jul-Sep) 2020-21

2020-21

Press Release Q3 (Oct-Dec) 2020-21

2020-21

Earnings Call Transcript Q4 (Jan-Mar) 2020-21

2020-21

Press Release Q4 (Jan-Mar) 2020-21

2020-21

Q1(Apr-Jun) 2019-20

2019-20

Q2(Jul-Sep) 2019-20

2019-20

Q3(Oct-Dec) 2019-20

2019-20

Q4(Jan-Mar) 2019-20

2019-20

Q1(Apr-Jun) 2018-19

2018-19

Q2(Jul-Sep) 2018-19

2018-19

Q3(Oct-Dec) 2018-19

2018-19

Q4(Jan-Mar) 2018-19

2018-19

Q1(Apr-Jun) 2017-18

2017-18

Q2(Jul-Sep) 2017-18

2017-18

Q3(Oct-Dec) 2017-18

2017-18

Q4(Jan-Mar) 2017-18

2017-18

Earnings Call Audio Q1 (Apr-Jun) 2021-22

2021-22

Earnings Call Audio Q2 (Jul-Sep) 2021-22

2021-22

Earnings Call Audio Q3 (Oct-Dec) 2021-22

2021-22

Earnings Call Audio Q4 (Jan-Mar) 2021-22

2021-22

Earnings Call Audio Q4 (Jan-Mar) 2020-21

2020-21

Investor Presentation Q4 (Jan-Mar) 2021-22

2021-22

Investor Presentation Q3 (Oct-Dec) 2021-22

2021-22

Investor Presentation Q2 (Jul-Sep) 2021-22

2021-22

Investor Presentation Q1 (Apr-Jun) 2021-22

2021-22

Investor Presentation Q4 (Jan-Mar) 2020-21

2020-21

Investor Presentation Q3 (Oct-Dec) 2020-21

2020-21

Q4(Jan-Mar) 2016-17

2016-17

Q3(Oct-Dec) 2016-17

2016-17

Q2(Jul-Sep) 2016-17

2016-17

Q1(Apr-Jun) 2016-17

2016-17

Q4(Jan-Mar) 2015-16

2015-16

Q3(Oct-Dec) 2015-16

2015-16

Q2(Jul-Sep) 2015-16

2015-16

Q1(Apr-Jun) 2015-16

2015-16

Q4(Jan-Mar) 2014-15

2014-15

Q3(Oct-Dec) 2014-15

2014-15

Q2(Jul-Sep) 2014-15

2014-15

Q1(Apr-Jun) 2014-15

2014-15

Q4(Jan-Mar) 2013-14

2013-14

Q3(Oct-Dec) 2013-14

2013-14

Investor Presentation Q2 (Jul-Sep) 2020-21

2020-21

Q2(Jul-Sep) 2013-14

2013-14

Investor Presentation Q1 (Apr-Jun) 2020-21

2020-21

Q1(Apr-Jun) 2013-14

2013-14

Investor Presentation Q4(Jan-Mar) 2019-20

2019-20

Investor Presentation Q3 (Oct-Dec) 2019-20

2019-20

Investor Presentation Q2 (Jul-Sep) 2019-20

2019-20

Investor Presentation Q1 (Apr-Jun) 2019-20

2019-20

Investor Presentation Q4 (Jan-Mar) 2018-19

2018-19

Investor Presentation Q3 (Oct-Dec) 2018-19

2018-19

Investor Presentation Q2 (Jul-Sep) 2018-19

2018-19

Investor Presentation Q1 (Apr-Jun) 2018-19

2018-19

Investor Presentation Q4 (Jan-Mar) 2017-18

2017-18

Investor Presentation Q3 (Oct-Dec) 2017-18

2017-18

Investor Presentation Q2 (Jul-Sep) 2017-18

2017-18

Investor Presentation Q1 (Apr-Jun) 2017-18

2017-18

Investor Presentation Q4 (Jan-Mar) 2016-17

2016-17

Investor Presentation Q3 (Oct-Dec) 2016-17

2016-17

Investor Presentation Q2 (Jul-Sep) 2016-17

2016-17

Investor Presentation Q1(Apr-Jun) 2016-17

2016-17

Investor Presentation Q4 (Jan-Mar) 2015-16

2015-16

Investor Presentation Q3 (Oct-Dec) 2015-16

2015-16

Investor Presentation Q2 (Jul-Sep) 2015-16

2015-16

Investor Presentation Q1 (Apr-Jun) 2015-16

2015-16

Investor Presentation Q4 (Jan-Mar) 2014-15

2014-15

Investor Presentation Q3 (Oct-Dec) 2014-15

2014-15

Investor Presentation Q2 (Jul-Sep) 2014-15

2014-15

Investor Presentation Q1 (Apr-Jun) 2014-15

2014-15

Press Release Q1 (Apr-Jun) 2022-23

2022-23

Investor Presentation Q1 (Apr-Jun) 2022-23

2022-23

Earnings Call Audio Q1 (Apr-Jun) 2022-23

2022-23

Earnings Call Transcript Q1 (Apr-Jun) 2022-23

2022-23

Press Release Q2 (Jul-Sep) 2022-23

2022-23

Investor Presentation Q2 (Jul-Sep) 2022-23

2022-23

Earnings Call Audio Q2 (Jul-Sep) 2022-23

2022-23

Earnings Call Transcript Q2 (Jul-Sep) 2022-23

2022-23

Investor Presentation (Nov 2022)

2022-23

Press Release Q3 (Oct-Dec) 2022-23

2022-23

Investor Presentation Q3 (Oct-Dec) 2022-23

2022-23

Earnings Call Audio Q3 (Oct-Dec) 2022-23

2022-23

Earnings Call Transcript Q3 (Oct-Dec) 2022-23

2022-23

Investor Presentation Q4 (Jan-Mar) 2022-23

2022-23

Earnings Call Audio Q4 (Jan-Mar) 2022-23

2022-23

Press Release Q4 (Jan-Mar) 2022-23

2022-23

Earnings Call Transcript Q4 (Jan-Mar) 2022-23

2022-23

Press Release Q1 (Apr-Jun) 2023-24

2023-24

Investor Presentation Q1 (Apr-Jun) 2023-24

2023-24

Earnings Call Audio Q1 (Apr-Jun) 2023-24

2023-24

Earnings Call Transcript Q1 (Apr-Jun) 2023-24

2023-24

Press Release Q2 (Jul-Sep) 2023-24

2023-24

Investor Presentation Q2 (Jul-Sep) 2023-24

2023-24

Earnings Call Audio Q2 (Jul-Sep) 2023-24

2023-24

Earnings Call Transcript Q2 (Jul-Sep) 2023-24

2023-24

Press Release Q3 (Oct-Dec) 2023-24

2023-24

Investor Presentation Q3 (Oct-Dec) 2023-24

2023-24

Earnings Call Audio Q3 (Oct-Dec) 2023-24

2023-24

Earnings Call Transcript Q3 (Oct-Dec) 2023-24

2023-24

Press Release Q4 (Jan-Mar) 2023-24

2023-24

Investor Presentation Q4 (Jan-Mar) 2023-24

2023-24

Earnings Call Audio Q4 (Jan-Mar) 2023-24

2023-24

Earnings Call Transcript Q4 (Jan-Mar) 2023-24

2023-24

Press Release Q1 (Apr-Jun) 2024-25

2024-25

Investor Presentation Q1 (Apr-Jun) 2024-25

2024-25

Earnings Call Audio Q1 (Apr-Jun) 2024-25

2024-25

Earnings Call Transcript Q1 (Apr-Jun) 2024-25

2024-25

Press Release Q2 (Jul-Sep) 2024-25

2024-25

Investor Presentation Q2 (Jul-Sep) 2024-25

2024-25

Earnings Call Audio Q2 (Jul-Sep) 2024-25

2024-25

Earnings Call Transcript Q2 (Jul-Sep) 2024-25

2024-25

As on 31st Mar 2019

2018-19

As on 31st December 2018

2018-19

As on 30th September 2018

2018-19

As on 30th June 2018

2018-19

As on 31st March 2020

2019-20

As on 31st December 2019

2019-20

As on 30th September 2019

2019-20

As on 30th June 2019

2019-20

As on 31st March 2021

2020-21

As on 31st December 2020

2020-21

As on 30th September 2020

2020-21

As on 30th June 2020

2020-21

As on 31st March 2022

2021-22

As on 31st December 2021

2021-22

As on 30th September 2021

2021-22

As on 30th June 2021

2021-22

As on 30th June 2022

2022-23

As on 31st March 2016

2015-16

As on 31st December 2015

2015-16

As on 30th September 2015

2015-16

As on 30th June 2015

2015-16

As on 31st March 2017

2016-17

As on 31st December 2016

2016-17

As on 30th September 2016

2016-17

As on 30th June 2016

2016-17

As on 31st March 2018

2017-18

As on 31st December 2017

2017-18

As on 30th September 2017

2017-18

As on 30th June 2017

2017-18

As on 30th September 2022

2022-23

As on 31st December 2022

2022-23

As on 31st March 2023

2022-23

As on 30th June 2024

2024-25

As on 30th September 2023

2023.24

As on 31st December 2023

2023.24

As on 31st March 2024

2023.24

As on 30th September 2024

2024-25

As on 31st December 2024

2024-25

At Ajanta, we have a well-defined environmental, health and safety policy. The policy covers the company, all our subsidiaries, and the contractors working for us.

We recognise our responsibility to address climate change and global warming which are posing long-term challenges. We ensure that the business is run in a socially, ecologically and economically responsible manner to minimise the impact. Our efforts in this regard are manifested by diligently complying with applicable laws and regulations, and taking proactive measures to maintain ecological balance.

EC Compliance Report

EC Letter Waluj Plant

SEIAA Letter for Ajanta Tower

Environment Audit Report 2023

Advertisements given after EC

EC Letter Ajanta Tower 2023

Dahej, Gujarat

Dosage Forms: Tablets, Capsules & Oral Suspension

Paithan, Aurangabad

Dosage Forms: Tablets, Capsules & Oral Suspension

Guwahati, Assam

Dosage Forms: Tablets, Capsules, Ointments, Jelly and Sterile Eye Drops

Pithampur, Madhya Pradesh

Dosage Forms: Tablets and Capsules

Chitegaon, Aurangabad

Dosage Forms: Tablets, Capsules, Oral Suspension & Jelly

Chikalthana, Aurangabad

Dosage Forms: Liquid and Capsules

API Waluj, Aurangabad

Dosage Forms: Active Pharma Ingredient

At Ajanta Pharma we are passionate about every product we deliver to our customers.

We operate 7 state-of-the-art manufacturing facilities in India boasting best-in-class equipment. Out of this, 6 facilities manufacture finished formulations and 1 manufactures Active Pharmaceutical Ingredients (APIs), for captive consumption. Stringent authorities like the US FDA and WHO have approved our facilities at Paithan in Maharashtra and Dahej in Gujarat.

At Ajanta quality assurance and quality control are given paramount importance. This is where we will never compromise.

Highest importance is given to this area to ensure that only the best of the products reach the customers. Our Quality Assurance (QA) systems harmonize and simplify CGMP processes to ensure sustainable quality culture across all our manufacturing sites. This includes QMS, CAPA, change control, complaint management, deviations, etc. which are reviewed and accepted by stringent regulatory authorities across the world.

Fortune India - Top 500 Companies

ET Prime - Ajanta Pharma has a way with out-of-the-box ideas

Business Today - India Most Valuable Companies

Business Today - Leaderspeak

Fortune India - Top 500 Companies

Business Today - India Best CEO to MD

Business India - Next Super 100 Companies

Business World - Real 500

Business India - Bucking the Trend

Business World - Indians Most Valuable CEO to MD

Business Outlook - The Out-performers

Forbes - APL Listed in Top 50 Companies in India

Deloitte Interview with MD

Corporate Brochure

Mr. Yogesh Agrawal, MD

Mr. Rajesh Agrawal, Jt. MD

Clonidine Hydrochloride Extended Release Tablets Approval & Launch

2017-18

US FDA approval for Entacapone Tablets

2017-18

Eletriptan Hydrobromide Launch in US

2017-18

Press release on resignation of Director

2018-19

Ajanta Employee Contribution Press Release

2020-21

Press Release Covid Contribution

2020-21

Press Release Buy back 2021

2021-22

Press Release Q2 (Jul-Sep) 2021-22

2021-22

Ajanta contributes Rs. 1 cr. to Maharashtra CM Relief Fund

2021-22

Press Release Q1 (Apr-Jun) 2021-22

2021-22

Press Release Q1 (Apr-Jun) 2022-23

2022-23

Press Release Q3 (Oct-Dec) 2021-22

2021-22

Press Release Q4 (Jan-Mar) 2021-22

2021-22

Ajanta Pharma awarded Best Managed Companies 2022 by Deloitte

2022-23

Press Release Q2 (Jul-Sep) 2022-23

2022-23

Press Release Q3 (Oct-Dec) 2022-23

2022-23

Press Release Q4 (Jan-Mar) 2022-23

2022-23

Press Release Q1 (Apr-Jun) 2023-24

2023-24

Press Release Q2 (Jul-Sep) 2023-24

2023-24

Press Release Q3 (Oct-Dec) 2023-24

2023-24

Press Release Q4 (Jan-Mar) 2023-24

2023-24

Press Release Q1 (Apr-Jun) 2024-25

2024-25

Press Release Q2 (Jul-Sep) 2024-25

2024-25

Memorandum & Articles of Association

Changes to the Privacy Policy:

Ajanta Pharma reserves the right to revise, change amend or alter and will notify the same accordingly by the appropriate medium, if we make any substantial changes in the way we use your Personal Information.

If you have questions about this Policy, please contact Ajanta Pharma by email at info@ajantapharma.com

User Consent

Ajanta Pharma Limited (Ajanta Pharma) respects the privacy of the visitors to the Site. This Privacy Policy is intended to inform you of our policies and practices regarding the collection, use, and disclosure of any Personal Information you submit to us through the Site. By submitting Personal Information through the Site, you agree to the terms of this Privacy Policy and you expressly consent to the processing of your Personal Information according to this Privacy Policy. By viewing and accessing this site you represent that you have read and understood this entire privacy policy and agree to all the terms of privacy policy. If you do not consent to this privacy policy in its entirety, your sole and exclusive remedy is to immediately cease use of this site. We, at Ajanta Pharma endeavour to ensure and maintain the privacy and security of all personal information collected or retrieved by your use, as a visitor of our website. The term "personal data" as used in this Policy refers to information such as your name, birth date, e-mail address or mailing address, etc. Ajanta Pharma pledges to comply with internationally recognized standards of privacy protection.

Intended Use of Personal Data

Most of the sections of our website do not require any form of registration and/or creation of account. However, if some sections of our website require registration, such registration shall be at your discretion and you may choose not to register with us, however in such event you will not be able to access such section. In the event you choose to register, you may need to fill in certain fields to gain full access to such section of the site by choosing a user name and password and/or for us to respond to your query.

Ajanta Pharma may collect and use personal data to provide information to you about us, to market products and services, to process orders or applications submitted by you, to create products or services to meet your needs, to seek your feedback or to contact you in relation to those services offered on our websites, to provide you educative Information to help resolve your problem and/or to help build your knowledge as also to allow you to subscribe to our newsletters.

Ajanta Pharma keeps your data and all information received only for as long as is reasonably necessary for such above mentioned purposes and in compliance with applicable laws in India, in relation to legal or ethical reporting or documentation retention requirements. Every effort has been made to keep the data and all information received safe and secure but we advise users to use this website at their own discretion.

This website is not intended nor aimed for the use or access by children below 18 years of age.

Non-Disclosure of Information

Ajanta Pharma will not sell, share, or otherwise distribute your personal data to third parties without your prior consent. However, if it is necessary to provide the same to a third party for further processing or in connection with its business, it will be in accordance with the applicable law for the purpose for which the data were originally collected. Ajanta Pharma will, wherever possible, endeavour to ensure that the disclosure and intended use of the data are clearly indicated and that such third parties provide the same level of protection as Ajanta Pharma.

Right of Access

If we have collected your personal data, you have the right to update your personal data. If you wish to review or change the details you have supplied to us, please contact the Company. However such review will be available only in accordance with our data retention policy. We are not obliged to store your data for a period which is beyond the intended purpose for which such data was collected or submitted.

Security And Confidentiality

To ensure the security and confidentiality of personal data that Ajanta Pharma collects on-line, Ajanta Pharma uses data networks protected, inter alia, by industry standard firewall and password protection. Access to personal data is restricted to only those employees on a need to know basis for the sole purpose of preserving the data and who are otherwise authorized and trained to handle such data properly. Staff compliance with our policies and procedures is regularly reviewed. While we cannot guarantee against any loss, misuse or alteration to data, we strive to prevent any such unfortunate occurrences.

Data Transfer Abroad

Ajanta Pharma is a global enterprise and may have databases in different jurisdictions. Ajanta Pharma, if required, may transfer your data to one of its databases outside your country of domicile. In such event if the level of privacy protection in such country of database does not comply with recognized international standards, we will ensure that data transfers to such databases in that country are adequately protected and that the transfer of data to third parties in such countries will not occur unless Ajanta Pharma implements the standards it generally follows to maintain the personal data.

Anonymous Data and

Most of the information that Ajanta Pharma collects from its website(s) is anonymous information, such as the pages you visit and the searches you perform. Anonymous information is processed by Ajanta Pharma to help improve the contents of the site and to compile aggregate statistics about individuals using our site for internal, market research purposes. In so doing, Ajanta Pharma may install "cookies" that collect the first level domain name of the user and the date and time of access. "Cookies" by themselves cannot be used to discover the identity of the user. A "cookie" is a small piece of information, which is sent to your browser and stored on your computer’s hard drive. Cookies do not damage your computer. You can set your browser to notify you when you receive a "cookie", this will enable you to decide if you want to accept it or not.

Spamming

Ajanta Pharma does not condone "spamming". Spamming is defined as sending unsolicited e-mails, usually of a commercial nature, in large numbers and repeatedly to individuals with whom the sender has had no previous contact or who have declined to receive such communications. In contrast, Ajanta Pharma may inform all its visitors of its products, health, or other related information by e-mail, whilst giving you the choice of opting out of such service.

Links to Other Sites

This Privacy Policy applies only to Ajanta Pharma’s websites. Ajanta Pharma may provide links to other websites, which we believe, may be of interest to our visitors. We try to ensure that such websites are of the highest standard. However, Ajanta Pharma does not guarantee the standards of every website link it provides or be responsible for the contents of non-Ajanta Pharma sites. The risk of accessing such websites is solely yours. Users should therefore note they click on external links at their own risk and this website and its owners cannot be held liable for any damages or implications caused by visiting any external links mentioned.

Social Media Platforms

Communication, engagement and actions taken through external social media platforms that this website and its owners participate on are custom to the terms and conditions as well as the privacy policies held with each social media platform respectively.

Users are advised to use social media platforms wisely and communicate / engage upon them with due care and caution in regard to their own privacy and personal details. This website nor its owners will ever ask for personal or sensitive information through social media platforms and encourage users wishing to discuss sensitive details to contact them through primary communication channels such as by telephone or email.

This website may use social sharing buttons which help share web content directly from web pages to the social media platform in question. Users are advised before using such social sharing buttons that they do so at their own discretion and note that the social media platform may track and save your request to share a web page respectively through your social media platform account.

No Paid Services Offered

Unless otherwise stated, this website does not offer you to access any content on payment basis. The access to the content of the website is only on "read-only" basis.

At Ajanta science is at our heart as we embrace R&D as an integral part of our business strategy. We have been consistently investing in it for decades.

Our core strength lies in our ability to excel in developing differentiated generic products backed by our dedicated teams in formulations development, process chemistry, and analytical development. This has helped in building a competitive advantage.